Your session is about to expire
← Back to Search
Mirtazapine for Brain Tumor
Study Summary
This trial will study whether mirtazapine can help reduce depression, nausea, vomiting, and weight loss in people with glioma who are undergoing temozolomide therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I will be treated with temozolomide as part of my cancer care.I stopped taking antidepressants at least a month ago.I have never been treated with temozolomide.I am allergic to Mirtazapine and certain nausea medications.I have received chemotherapy for brain cancer before.My diagnosis is glioma, confirmed through tissue examination.Your doctors think you may not live for more than three months.I need some help with daily activities but can care for most of my personal needs.You are pregnant or breastfeeding.I am 18 or older and understand English well enough to comprehend consent forms and study materials.
- Group 1: mirtazapine in glioma patients treated with Temozolomide
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elaborate on other case studies that have used Mirtazapine (Remeron)?
"Mirtazapine, or Remeron, is being trialed in 225 different clinical studies. 27 of those trials have progressed to Phase 3 testing. Most of the tests are taking place in Seoul and Songpa, South Korea; though, there are 4,849 total locations running trials for this medication."
Are there any well-documented dangers to taking Mirtazapine (Remeron)?
"While there is some data supporting Mirtazapine's safety, it did not receive a score of 3 because there is no efficacy data."
does this research project investigating a new treatment have precedent?
"First studied in 2002, Mirtazapine (Remeron) completed its first clinical trial with 60 participants. The drug sponsor was Schering-Plough. After the success of the initial study, Mirtazapine (Remeron) received Phase 2 approval and is now being trialed in 225 separate cases across 950 cities and 37 countries."
What is the most popular application of Mirtazapine (Remeron)?
"Mirtazapine (Remeron) is typically used to plan for end-of-life care. However, it can also be prescribed to treat refractory neuroblastoma, panic attacks, and major depressive disorder."
How many test subjects are there in this experiment?
"That is correct, the website clinicaltrials.gov has information stating that this trial is looking for volunteers right now. The listing says that the trial was first posted on February 26th, 2019 and updated April 15th, 2021. They are hoping to find 120 patients willing to participate at 1 location."
Are we still looking for participants in this clinical trial?
"The clinical trial detailed on clinicaltrials.gov is currently recruiting patients. This research was originally made public on February 26th, 2019 with the most recent update taking place on April 15th, 2021."
Share this study with friends
Copy Link
Messenger